Holen Sie sich die Stockscreener-App
27.55
1.61%
-0.45
Handel nachbörslich:
27.29
-0.26
-0.94%
Schlusskurs vom Vortag:
$28.00
Offen:
$28.17
24-Stunden-Volumen:
1.15M
Relative Volume:
0.56
Marktkapitalisierung:
$2.80B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-15.22
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
+1.51%
1M Leistung:
+4.04%
6M Leistung:
+28.38%
1J Leistung:
+2.80%
1-Tages-Spanne:
$27.29
$28.71
1-Wochen-Bereich:
$26.33
$30.50
52-Wochen-Spanne:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie BEAM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.55 | 2.84B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Eingeleitet | Jefferies | Buy |
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Aug Analyst Calls: Will Beam Therapeutics Inc. stock benefit from infrastructure spendingTreasury Yields & Free Community Supported Trade Ideas - ulpravda.ru
Will Beam Therapeutics Inc. stock reach all time highs in 2025Treasury Yields & Proven Capital Preservation Methods - ulpravda.ru
Behavioral Patterns of BEAM and Institutional Flows - Stock Traders Daily
What catalysts could drive Beam Therapeutics Inc. stock higherGap Down & Real-Time Buy Zone Alerts - ulpravda.ru
Will Beam Therapeutics Inc. stock beat EPS estimatesMarket Risk Summary & Weekly Watchlist for Consistent Profits - ulpravda.ru
What dividend safety score for Beam Therapeutics Inc. stock2025 EndofYear Setup & Daily Technical Stock Forecast Reports - ulpravda.ru
How resilient is Beam Therapeutics Inc. stock in market downturnsWatch List & Low Drawdown Momentum Ideas - ulpravda.ru
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Bank of America Securities Reaffirms Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
UBS Initiates Coverage of Beam Therapeutics (BEAM) with Neutral Recommendation - Nasdaq
Is Beam Therapeutics Inc. stock a defensive play in 2025Resistance Zone Identification & Free High Profit Capital Plays - ulpravda.ru
UBS Initiates Coverage on Beam Therapeutics (BEAM) with Neutral - GuruFocus
UBS Initiates Beam Therapeutics at Neutral With $28 Price Target - MarketScreener
Beam Therapeutics stock initiated with Neutral rating by UBS - Investing.com Australia
How Investors Are Reacting To Beam Therapeutics (BEAM) ARK’s Renewed Bet On Base-Editing Biotech - Yahoo Finance
Beam Therapeutics stock rises 5% after BofA lifts target to $45 - TechStock²
Beam Therapeutics (NASDAQ:BEAM) Shares Up 11.1%What's Next? - MarketBeat
Will Beam Therapeutics Inc. stock benefit from infrastructure spendingStock Price Forecasts & Low Cost Wealth Building - bollywoodhelpline.com
BofA Adjusts Price Target on Beam Therapeutics to $45 From $43, Maintains Buy Rating - MarketScreener
Beam Therapeutics soars 64% after InvestingPro’s undervalued call in April By Investing.com - Investing.com South Africa
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure - Yahoo Finance
ARK Invest Boosts Stake in Beam Therapeutics (BEAM) Amid Biotech Focus - GuruFocus
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Hold at Wall Street Zen - MarketBeat
Beam Therapeutics stock initiated with Neutral rating by UBS By Investing.com - Investing.com Nigeria
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? - The Globe and Mail
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Sahm
Beam Therapeutics Inc. (BEAM) reports updated data from BEACON Phase 1/2 Trial of Ristoglogene - MSN
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab - TradingView — Track All Markets
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene - Finviz
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? - Yahoo Finance
(BEAM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
BMO Capital maintains Outperform on Beam Therapeutics stock - MSN
12 Best Genomics Stocks to Invest In - Insider Monkey
Death Cross: Is Beam Therapeutics Inc. stock a defensive play in 2025Exit Point & Safe Entry Zone Identification - moha.gov.vn
Beam Therapeutics (BEAM) Is Up 9.9% After BEACON Data Boosts Confidence In Risto-cel Therapy - simplywall.st
Beam Therapeutics Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy - Finviz
Prime Editing & CRISPR Market Set to Revolutionize Gene Therapy: - openPR.com
Growth Value: Will Beam Therapeutics Inc. stock benefit from infrastructure spending2025 Price Action Summary & Short-Term High Return Strategies - Улправда
Is Beam Therapeutics Inc. stock a safe investment in uncertain marketsWeekly Trading Summary & Daily Price Action Insights - Улправда
Targets Report: What margin trends mean for Beam Therapeutics Inc. stockPortfolio Performance Report & Expert Approved Trade Ideas - Улправда
Growth Report: Is Beam Therapeutics Inc. stock attractive for retirement portfoliosJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
Is Beam Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Report & Short-Term High Return Strategies - Улправда
Price-Driven Insight from (BEAM) for Rule-Based Strategy - Stock Traders Daily
Aug Final Week: Is Beam Therapeutics Inc. stock a defensive play in 2025July 2025 EndofMonth & Free Community Consensus Stock Picks - ulpravda.ru
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
What margin trends mean for Beam Therapeutics Inc. stockEarnings Risk Summary & Reliable Volume Spike Alerts - ulpravda.ru
Beam Therapeutics Inc. $BEAM Shares Acquired by Squarepoint Ops LLC - MarketBeat
Is Beam Therapeutics Inc. stock attractive for retirement portfoliosJuly 2025 EndofMonth & Reliable Price Breakout Signals - Улправда
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beam Therapeutics Inc-Aktie (BEAM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bellon Christine | Chief Legal Officer |
Dec 31 '25 |
Sale |
27.10 |
1,254 |
33,983 |
115,667 |
| FMR LLC | See Remark 1 |
Oct 27 '25 |
Sale |
26.68 |
459 |
12,246 |
14 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Oct 01 '25 |
Sale |
24.53 |
467 |
11,456 |
44,045 |
| Bellon Christine | Chief Legal Officer |
Oct 01 '25 |
Sale |
24.53 |
373 |
9,150 |
116,921 |
| Evans John M. | CEO |
Oct 01 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Sale |
24.63 |
25,000 |
615,668 |
986,667 |
| Evans John M. | CEO |
Oct 01 '25 |
Sale |
24.51 |
25,000 |
612,655 |
986,667 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):